Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Key Points

• Abeona Therapeutics missed quarterly estimates, reporting an EPS loss of $0.35 versus the $0.23 expected and revenue of $11.38 million versus $12.24 million. The net loss widened to $20.2 million, while the stock fell 15.6% to $6.30.
• ZEVASKYN revenue increased 31% quarter over quarter, supported by treatment expansion to seven activated centers and 12 patients treated since launch. Abeona ended the quarter with $146.8 million in cash and investments.
• Launch execution faced cancellations, a low-yield batch and an out-of-specification batch, resulting in two non-billable treatments. However, CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, which could improve hospital economics and payer negotiations.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.12), FiscalAI reports. The company had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million.

Here are the key takeaways from Abeona Therapeutics' conference call:

• ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million, with four revenue-generating treatments recognized in the second quarter. Abeona ended June with $146.8 million in cash, cash equivalents, and short-term investments.
• The commercial rollout expanded to seven activated qualified treatment centers, and 12 patients have been treated since launch, including five in Q2 and three more in Q3 to date. The company estimates about 40% of its addressable market now has in-state access to a treatment center.
• Launch execution remains operationally complex, with scheduling disruptions, two last-minute biopsy cancellations, one low-yield batch, and one out-of-specification batch. Both affected patients were treated, but Abeona will recognize no revenue for those two treatments and said the long-term rate of non-billable units remains uncertain.
• CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, making it one of only three of 15 traditional-pathway applicants to receive the designation. Although Medicare represents roughly 10% of the payer mix, Abeona expects NTAP to improve hospital economics and potentially support broader payer negotiations.
• Abeona reported a second-quarter net loss of $20.2 million, or $0.35 per share, compared with a $17.1 million loss in Q1. Gross margin was approximately 63%, though management expects margins could reach 85%–90% at steady-state volume as fixed manufacturing costs are spread across more treatments.

Abeona Therapeutics Trading Down 15.6%

ABEO stock traded down $1.16 during midday trading on Thursday, hitting $6.30. 4,143,475 shares of the company's stock were exchanged, compared to its average volume of 1,238,725. The stock has a market capitalization of $358.92 million, a PE ratio of 6.50 and a beta of 1.35. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. Abeona Therapeutics has a 1-year low of $4.00 and a 1-year high of $7.65. The business has a 50-day simple moving average of $6.29 and a two-hundred day simple moving average of $5.56.

Insider Buying and Selling at Abeona Therapeutics

In related news, Director Leila Alland sold 11,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $5.92, for a total transaction of $65,120.00. Following the completion of the sale, the director owned 162,614 shares of the company's stock, valued at approximately $962,674.88. This represents a 6.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Madhav Vasanthavada sold 12,606 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total transaction of $87,737.76. Following the sale, the insider directly owned 290,623 shares in the company, valued at $2,022,736.08. This trade represents a 4.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 307,221 shares of company stock worth $1,854,494. 7.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG grew its stake in shares of Abeona Therapeutics by 6.2% during the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company's stock worth $207,000 after purchasing an additional 2,303 shares during the period. LPL Financial LLC raised its holdings in Abeona Therapeutics by 5.3% in the fourth quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company's stock worth $331,000 after purchasing an additional 3,165 shares during the period. Intech Investment Management LLC boosted its position in shares of Abeona Therapeutics by 19.6% during the third quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company's stock worth $133,000 after purchasing an additional 4,127 shares in the last quarter. Creative Planning boosted its position in shares of Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock worth $81,000 after purchasing an additional 4,305 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Abeona Therapeutics during the second quarter worth $27,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ABEO shares. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Abeona Therapeutics in a report on Thursday, May 28th. Wall Street Zen upgraded Abeona Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings cut Abeona Therapeutics from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, August 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source